Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
Executive Summary
The oncology player missed out on the first round of immune checkpoint inhibition and now some investors are wondering if the pharma needs to buy a rival to catch up. During the company’s second quarter sales call CEO Jimenez insisted Novartis has the internal expertise to execute.
You may also be interested in...
Novartis' CAR-T CTL019 Back On The Blockbuster Hit List
CEO Joe Jimenez told investors the firm is encouraged about the commercial prospects for CAR-T therapy. Lead drug CTL019 made Novartis' list of blockbusters in development after having been left off last year.
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.
Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III
Partnered on chronic heart failure drug omecamtiv mecarbil, Amgen and Cytokinetics took months to design a Phase III trial that would address the needs and concerns of both payers and clinicians.